Multiple sclerosis trials in Bulgaria

In Bulgaria 10 Also abroad 506

10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Pleven, Plovdiv, Sofiya, Veliko Tirnovo
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Pleven, Plovdiv, Sofiya, Veliko Tirnovo
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Blagoevgrad, Pazardzhik, Pleven, Sofiya
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 3Taking people
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Where
Pleven, Sofia, Sofiya
Age
18 years and over
People
500 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06675955 · EU 2023-507633-21-01
Phase 2Taking people
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
Where
Blagoevgrad, Burgas, Pleven, Plovdiv, Ruse, Shumen, Sofia, Sofiya, Varna
Age
18 years to 64 years
People
230 worldwide
Run by
Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00
Phase 3Taking people
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Where
Pleven, Sofiya
Age
18 years to 64 years
People
125 worldwide
Run by
Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Pleven, Sofia
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Blagoevgrad, Pleven, Sofia, Sofiya
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Lovech, Montana, Pleven, Sofia, Sofiya
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00
Phase 1Not yet taking people in Bulgaria
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
Where
Pleven, Plovdiv, Sofia, Sofiya
Age
18 years to 65 years
People
222 worldwide
Run by
Polpharma Biologics International AG
See details and how to joinNCT07606521 · EU 2026-525314-61-00